151 related articles for article (PubMed ID: 282625)
1. Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway.
Nydegger UE; Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1978 Dec; 75(12):6078-82. PubMed ID: 282625
[TBL] [Abstract][Full Text] [Related]
2. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
Fearon DT
Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
4. An autosomal dominant gene regulates the extent of 9-O-acetylation of murine erythrocyte sialic acids. A probable explanation for the variation in capacity to activate the human alternate complement pathway.
Varki A; Kornfeld S
J Exp Med; 1980 Sep; 152(3):532-44. PubMed ID: 7411019
[TBL] [Abstract][Full Text] [Related]
5. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
Lambré CR; Kazatchkine MD; Maillet F; Thibon M
J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
[TBL] [Abstract][Full Text] [Related]
6. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
7. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
[TBL] [Abstract][Full Text] [Related]
8. A molecular basis of activation of the alternative pathway of human complement.
Austen KF; Fearon DT
Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
[TBL] [Abstract][Full Text] [Related]
9. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
10. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes.
Van Dijk H; Rademaker PM; Willers JM
J Immunol Methods; 1980; 36(1):29-39. PubMed ID: 7204994
[TBL] [Abstract][Full Text] [Related]
11. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
12. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.
Meri S; Pangburn MK
Proc Natl Acad Sci U S A; 1990 May; 87(10):3982-6. PubMed ID: 1692629
[TBL] [Abstract][Full Text] [Related]
13. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
[TBL] [Abstract][Full Text] [Related]
15. Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes.
Czop JK; Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3831-5. PubMed ID: 278997
[TBL] [Abstract][Full Text] [Related]
16. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
17. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
Kazatchkine MD; Fearon DT; Austen KF
J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
[No Abstract] [Full Text] [Related]
18. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
[TBL] [Abstract][Full Text] [Related]
19. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the alternative pathway of human complement by structural analogues of sialic acid.
Michalek MT; Mold C; Bremer EG
J Immunol; 1988 Mar; 140(5):1588-94. PubMed ID: 3346543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
